Med BioGene Posts No Revenues in Q3 as Partner Validates Test | GenomeWeb

NEW YORK (GenomeWeb News) – Med BioGene said after the close of the market on Thursday that it had no revenues for the third quarter ended Sept. 30.

The firm had posted revenues of C$1.5 million (US$1.5 million) for the third quarter a year ago. The revenues last year were derived from licensing payments.

Med BioGene's net loss for the quarter was C$79,633, or break even on a per-share basis, compared to a profit of C$1.6 million, or C$.02 per share, a year ago, according to a document filed with Canadian regulators.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.